In this study, we realized that breast cancer patients with highly expressing NEDD4 show significantly reduced survival rates, specifically in poorly differentiated breast cancer types which are ER-negative breast cancer types, including HER2+ and TNBC (Figure 1A). Here, ERBB2 is linked to breast carcinoma.